Trial Profile
A multi-centre randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on the progression of left ventricular mass and diastolic function in patients with structural heart disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms Beta3-LVH
- 02 Nov 2021 Status changed from active, no longer recruiting to completed.
- 28 Sep 2021 Planned End Date changed from 1 Sep 2021 to 1 Sep 2022.
- 28 Sep 2021 Planned primary completion date changed from 1 Aug 2021 to 1 Aug 2022.